1,2-dichloroethane decreases expression ISO RGD:1316249 6480464 ethylene dichloride results in decreased expression of PBX3 mRNA CTD PMID:28189721 , PMID:28960355 17beta-estradiol decreases expression ISO RGD:1316248 6480464 Estradiol results in decreased expression of PBX3 mRNA CTD PMID:21185374 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1316249 6480464 Tetrachlorodibenzodioxin affects the expression of PBX3 mRNA CTD PMID:21570461 , PMID:24058054 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1316249 6480464 [TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PBX3 mRNA CTD PMID:25975270 2-hydroxypropanoic acid increases expression ISO RGD:1316248 6480464 Lactic Acid results in increased expression of PBX3 mRNA CTD PMID:30851411 2-methylcholine affects expression ISO RGD:1316248 6480464 beta-methylcholine affects the expression of PBX3 mRNA CTD PMID:21179406 3,4-methylenedioxymethamphetamine decreases expression EXP 6480464 N-Methyl-3, 4-methylenedioxyamphetamine results in decreased expression of PBX3 mRNA CTD PMID:30071829 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:1316248 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of PBX3 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of PBX3 mRNA CTD PMID:28628672 4,4'-sulfonyldiphenol multiple interactions ISO RGD:1316248 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of PBX3 mRNA CTD PMID:28628672 4-hydroxyphenyl retinamide increases expression ISO RGD:1316249 6480464 Fenretinide results in increased expression of PBX3 mRNA CTD PMID:28973697 5-fluorouracil affects response to substance ISO RGD:1316248 6480464 PBX3 protein affects the susceptibility to Fluorouracil CTD PMID:16217747 aflatoxin B1 decreases methylation ISO RGD:1316248 6480464 Aflatoxin B1 results in decreased methylation of PBX3 gene CTD PMID:27153756 aflatoxin M1 decreases expression ISO RGD:1316248 6480464 Aflatoxin M1 results in decreased expression of PBX3 mRNA CTD PMID:30928695 all-trans-retinoic acid increases expression ISO RGD:1316248 6480464 Tretinoin results in increased expression of PBX3 mRNA CTD PMID:23724009 all-trans-retinoic acid decreases expression ISO RGD:1316248 6480464 Tretinoin results in decreased expression of PBX3 mRNA CTD PMID:33167477 azathioprine decreases expression ISO RGD:1316248 6480464 Azathioprine results in decreased expression of PBX3 mRNA CTD PMID:22623647 benzo[a]pyrene decreases expression ISO RGD:1316249 6480464 Benzo(a)pyrene results in decreased expression of PBX3 mRNA CTD PMID:19770486 benzo[a]pyrene decreases methylation ISO RGD:1316248 6480464 Benzo(a)pyrene results in decreased methylation of PBX3 promoter CTD PMID:27901495 benzo[a]pyrene decreases expression EXP 6480464 Benzo(a)pyrene results in decreased expression of PBX3 mRNA CTD PMID:21839799 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of PBX3 mRNA CTD PMID:25181051 , PMID:30816183 bisphenol A multiple interactions ISO RGD:1316248 6480464 [bisphenol A co-treated with Fulvestrant] results in increased methylation of PBX3 gene CTD PMID:31601247 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of PBX3 mRNA CTD PMID:34947998 bisphenol A increases methylation EXP 6480464 bisphenol A results in increased methylation of PBX3 gene CTD PMID:28505145 bisphenol F multiple interactions ISO RGD:1316248 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of PBX3 mRNA CTD PMID:28628672 bisphenol F increases methylation ISO RGD:1316248 6480464 bisphenol F results in increased methylation of PBX3 gene CTD PMID:31601247 bortezomib decreases expression ISO RGD:1316248 6480464 Bortezomib results in decreased expression of PBX3 mRNA CTD PMID:20977926 butanal decreases expression ISO RGD:1316248 6480464 butyraldehyde results in decreased expression of PBX3 mRNA CTD PMID:26079696 carbamazepine affects expression ISO RGD:1316248 6480464 Carbamazepine affects the expression of PBX3 mRNA CTD PMID:25979313 carbon nanotube increases expression ISO RGD:1316249 6480464 Nanotubes, Carbon results in increased expression of PBX3 mRNA CTD PMID:25620056 CGP 52608 multiple interactions ISO RGD:1316248 6480464 CGP 52608 promotes the reaction [RORA protein binds to PBX3 gene] CTD PMID:28238834 choline multiple interactions ISO RGD:1316249 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of PBX3 gene CTD PMID:20938992 cisplatin multiple interactions ISO RGD:1316248 6480464 [Cisplatin co-treated with jinfukang] results in decreased expression of PBX3 mRNA CTD PMID:27392435 cobalt dichloride decreases expression EXP 6480464 cobaltous chloride results in decreased expression of PBX3 mRNA CTD PMID:24386269 cocaine increases expression ISO RGD:1316249 6480464 Cocaine results in increased expression of PBX3 mRNA CTD PMID:18355967 cocaine multiple interactions ISO RGD:1316249 6480464 FOS protein mutant form inhibits the reaction [Cocaine results in increased expression of PBX3 mRNA] CTD PMID:18355967 crocidolite asbestos decreases expression ISO RGD:1316248 6480464 Asbestos, Crocidolite results in decreased expression of PBX3 mRNA CTD PMID:29523930 cyclosporin A decreases expression ISO RGD:1316248 6480464 Cyclosporine results in decreased expression of PBX3 mRNA CTD PMID:20106945 cyclosporin A affects expression ISO RGD:1316248 6480464 Cyclosporine affects the expression of PBX3 mRNA CTD PMID:25562108 dexamethasone multiple interactions ISO RGD:1316248 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of PBX3 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of PBX3 mRNA CTD PMID:28628672 dibutyl phthalate decreases expression EXP 6480464 Dibutyl Phthalate results in decreased expression of PBX3 mRNA CTD PMID:21266533 dibutyl phthalate decreases expression ISO RGD:1316249 6480464 Dibutyl Phthalate results in decreased expression of PBX3 mRNA CTD PMID:17361019 , PMID:21266533 dorsomorphin multiple interactions ISO RGD:1316248 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PBX3 mRNA CTD PMID:27188386 doxorubicin decreases expression ISO RGD:1316248 6480464 Doxorubicin results in decreased expression of PBX3 mRNA CTD PMID:29803840 endosulfan increases expression EXP 6480464 Endosulfan results in increased expression of PBX3 mRNA CTD PMID:29391264 ethanol affects splicing ISO RGD:1316249 6480464 Ethanol affects the splicing of PBX3 mRNA CTD PMID:30319688 ethanol affects expression ISO RGD:1316249 6480464 Ethanol affects the expression of PBX3 mRNA CTD PMID:30319688 folic acid multiple interactions ISO RGD:1316249 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of PBX3 gene CTD PMID:20938992 folic acid decreases expression ISO RGD:1316249 6480464 Folic Acid results in decreased expression of PBX3 mRNA CTD PMID:25629700 fulvestrant multiple interactions ISO RGD:1316248 6480464 [bisphenol A co-treated with Fulvestrant] results in increased methylation of PBX3 gene CTD PMID:31601247 fulvestrant increases methylation ISO RGD:1316248 6480464 Fulvestrant results in increased methylation of PBX3 gene CTD PMID:31601247 gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of PBX3 mRNA CTD PMID:33387578 indometacin multiple interactions ISO RGD:1316248 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of PBX3 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of PBX3 mRNA CTD PMID:28628672 ketamine decreases expression EXP 6480464 Ketamine results in decreased expression of PBX3 mRNA CTD PMID:20080153 L-methionine multiple interactions ISO RGD:1316249 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of PBX3 gene CTD PMID:20938992 lead diacetate decreases expression ISO RGD:1316249 6480464 lead acetate results in decreased expression of PBX3 mRNA CTD PMID:22613225 methapyrilene increases expression EXP 6480464 Methapyrilene results in increased expression of PBX3 mRNA CTD PMID:30467583 methyl methanesulfonate increases expression ISO RGD:1316248 6480464 Methyl Methanesulfonate results in increased expression of PBX3 mRNA CTD PMID:23649840 methylmercury chloride decreases expression ISO RGD:1316248 6480464 methylmercuric chloride results in decreased expression of PBX3 mRNA CTD PMID:28001369 oxaliplatin decreases expression EXP 6480464 oxaliplatin results in decreased expression of PBX3 mRNA CTD PMID:25729387 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of PBX3 mRNA CTD PMID:25729387 paracetamol affects expression ISO RGD:1316249 6480464 Acetaminophen affects the expression of PBX3 mRNA CTD PMID:17562736 paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of PBX3 mRNA CTD PMID:33387578 paracetamol increases expression ISO RGD:1316248 6480464 Acetaminophen results in increased expression of PBX3 mRNA CTD PMID:22230336 phenobarbital decreases expression ISO RGD:1316249 6480464 Phenobarbital results in decreased expression of PBX3 mRNA CTD PMID:23091169 pirinixic acid multiple interactions ISO RGD:1316249 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of PBX3 mRNA CTD PMID:19710929 quercetin decreases expression ISO RGD:1316248 6480464 Quercetin results in decreased expression of PBX3 mRNA CTD PMID:21632981 rac-lactic acid increases expression ISO RGD:1316248 6480464 Lactic Acid results in increased expression of PBX3 mRNA CTD PMID:30851411 SB 431542 multiple interactions ISO RGD:1316248 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PBX3 mRNA CTD PMID:27188386 sodium arsenite decreases expression ISO RGD:1316248 6480464 sodium arsenite results in decreased expression of PBX3 mRNA CTD PMID:22714537 sunitinib decreases expression ISO RGD:1316248 6480464 Sunitinib results in decreased expression of PBX3 mRNA CTD PMID:31533062 tamoxifen increases expression ISO RGD:1316249 6480464 Tamoxifen results in increased expression of PBX3 mRNA CTD PMID:25123088 temozolomide decreases expression ISO RGD:1316248 6480464 Temozolomide results in decreased expression of PBX3 mRNA CTD PMID:31758290 tert-butyl hydroperoxide decreases expression ISO RGD:1316248 6480464 tert-Butylhydroperoxide results in decreased expression of PBX3 mRNA CTD PMID:15336504 tetrachloromethane increases expression ISO RGD:1316249 6480464 Carbon Tetrachloride results in increased expression of PBX3 mRNA CTD PMID:31919559 thapsigargin decreases expression ISO RGD:1316248 6480464 Thapsigargin results in decreased expression of PBX3 mRNA CTD PMID:29453283 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of PBX3 mRNA CTD PMID:34492290 toluene increases expression EXP 6480464 Toluene results in increased expression of PBX3 mRNA CTD PMID:22166486 topotecan decreases expression EXP 6480464 Topotecan results in decreased expression of PBX3 mRNA CTD PMID:25729387 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of PBX3 mRNA CTD PMID:25729387 trichostatin A decreases expression ISO RGD:1316248 6480464 trichostatin A results in decreased expression of PBX3 mRNA CTD PMID:24935251 triclosan increases expression ISO RGD:1316248 6480464 Triclosan results in increased expression of PBX3 mRNA CTD PMID:30510588 trovafloxacin decreases expression ISO RGD:1316249 6480464 trovafloxacin results in decreased expression of PBX3 mRNA CTD PMID:35537566 uranium atom affects expression ISO RGD:1316248 6480464 Uranium affects the expression of PBX3 mRNA CTD PMID:15672453 urethane increases expression ISO RGD:1316248 6480464 Urethane results in increased expression of PBX3 mRNA CTD PMID:28818685 valproic acid affects expression ISO RGD:1316249 6480464 Valproic Acid affects the expression of PBX3 mRNA CTD PMID:17292431 valproic acid increases expression ISO RGD:1316248 6480464 Valproic Acid results in increased expression of PBX3 mRNA CTD PMID:23179753 valproic acid affects expression ISO RGD:1316248 6480464 Valproic Acid affects the expression of PBX3 mRNA CTD PMID:25979313 valproic acid decreases expression ISO RGD:1316248 6480464 Valproic Acid results in decreased expression of PBX3 mRNA CTD PMID:26272509 , PMID:28001369 valproic acid multiple interactions ISO RGD:1316248 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PBX3 mRNA CTD PMID:27188386